Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics

Cited by (398)

Items 201–300 of 398

1. Comparative Anesthesia and Analgesia of Birds
   J. Ludders · 2017
2. Translation of Central Nervous System Occupancy from Animal Models: Application of Pharmacokinetic/Pharmacodynamic Modeling
   Murad R. Melhem · 2013 · Journal of Pharmacology and Experimental Therapeutics
3. Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins
   Yi Zhang, B. Meibohm · 2012 · Pharmaceutical biotechnology
4. Utility of the Coefficient of Determination (r2) in Assessing the Accuracy of Interspecies Allometric Predictions: Illumination or Illusion?
   Huadong Tang, Michael Mayersohn · 2007 · Drug Metabolism and Disposition
5. Noninvasive and nondestructive optical spectroscopic measurement of motexafin gadolinium in mouse tissues: comparison to high-performance liquid chromatography.
   S. Kanick, J. Eiseman, Erin Joseph, Jian-Xia Guo, R. Parker · 2007 · Journal of Photochemistry and Photobiology. B: Biology
6. Introduction to Pharmacometrics and Quantitative Pharmacology with an Emphasis on Physiologically Based Pharmacokinetics
   S. Sy, Xiao-Feng Wang, H. Derendorf · 2014 · AAPS advances in the pharmaceutical sciences series
7. Pharmacokinetics and toxicity of the antitumour agentN-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse
   J. Paxton, D. Young, Sean Evans, P. Kestell, I. G. Robertson, E. Cornford · 2004 · Cancer Chemotherapy and Pharmacology
8. Optimization of pig models for translation of subcutaneous pharmacokinetics of therapeutic proteins: Liraglutide, insulin aspart and insulin detemir
   Karen‐Margrethe Pedersen, Anna Katrina Jógvansdóttir Gradel, Trine Pagh Ludvigsen, Berit Østergaard Christoffersen, Caroline Amalie Fuglsang-Damgaard, Kristian Moss Bendtsen, Suzi Høgh Madsen, Valentina Manfé, Hanne H. F. Refsgaard · 2021 · Translational research
9. Biodistribution and translational pharmacokinetic modeling of a human recombinant alkaline phosphatase.
   Esther Peters, J. Stevens, Jacques Arend, Z. Guan, W. Raaben, P. Laverman, A. van Elsas, R. Masereeuw, P. Pickkers · 2015 · International journal of pharmaceutics
10. Pharmacokinetics and Interspecies Allometric Scaling of ST-246, an Oral Antiviral Therapeutic for Treatment of Orthopoxvirus Infection
    Adams Amantana, Yali Chen, Shanthakumar Tyavanagimatt, Kevin F. Jones, Robert Jordan, Jarasvech Chinsangaram, Tové C. Bolken, Janet M. Leeds, Dennis E. Hruby · 2013 · PLoS ONE
11. Pharmacokinetics and Pharmacodynamics of Peptide and Protein Therapeutics
    Bernd Meibohm · 2013 · Springer eBooks
12. Interspecies scaling of toxicity reference values in human health versus ecological risk assessments: A critical review
    Harvey J. Clewell III M.A., Phyllis C. Fuchsman · 2023 · Integrated Environmental Assessment and Management
13. Pre-clinical evaluation of a P. berghei-based whole-sporozoite malaria vaccine candidate
    A. Mendes, Isaie J. Reuling, C. M. Andrade, T. Otto, Marta Machado, F. Teixeira, Joana Pissarra, N. Gonçalves-Rosa, Dolores Bonaparte, João Sinfrónio et al. · 2018 · npj Vaccines
14. Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs
    Bin Yang, Chunnuan Wu, Bin Ji, Mingrui Wu, Zhonggui He, Lei Shang, Jin Sun · 2016 · Asian Journal of Pharmaceutical Sciences
15. Prediction of ACNU plasma concentration-time profiles in humans by animal scale-up
    Y. Mitsuhashi, Y. Sugiyama, S. Ozawa, T. Nitanai, K. Sasahara, Kan-ichi Nakamura, Miroru Tanaka, Takuzo Nishimura, M. Inaba, Tomowo Kobayashi · 2004 · Cancer Chemotherapy and Pharmacology
16. A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib
    E. Tosca, N. Terranova, K. Stuyckens, A. Dosne, T. Perera, J. Vialard, P. King, T. Verhulst, J. Pérez-Ruixo, P. Magni et al. · 2021 · Cancer Chemotherapy and Pharmacology
17. Interspecies Scaling of Human Clearance and Plasma Trough Exposure for Antisense Oligonucleotides: A Retrospective Analysis of GalNAc3-Conjugated and Unconjugated-Antisense Oligonucleotides
    Charvi Nanavati, Gina McMullen, Rosie Z. Yu, Richard S. Geary, Scott P. Henry, Yanfeng Wang · 2021 · Nucleic Acid Therapeutics
18. Effects of inter-alpha inhibitor proteins on brain injury after exposure of neonatal rats to severe hypoxia-ischemia
    Stephanie Schuffels, Sakura Nakada, Yuehua Wu, Y. Lim, Xiao-Di F. Chen, B. Stonestreet · 2020 · Experimental Neurology
19. Prediction of Human Clearance Based on Animal Data and Molecular Properties
    Wenkang Huang, Lv Geng, Rong Deng, Shaoyong Lu, Guangli Ma, Jianxiu Yu, Jian Zhang, Wei Liu, Tingjun Hou, Xuefeng Lü · 2015 · Chemical Biology & Drug Design
20. Non‐Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First‐in‐Human Dose Selection for CNTO 5825, an Anti‐Interleukin‐13 Monoclonal Antibody
    Ivo P. Nnane, Zhenhua Xu, Honghui Zhou, Hugh M. Davis · 2015 · Basic & Clinical Pharmacology & Toxicology
21. Quantifying and Communicating Uncertainty in Preclinical Human Dose-Prediction
    Monika Sundqvist, A. Lundahl, M. Nagard, U. Bredberg, P. Gennemark · 2015 · CPT: Pharmacometrics & Systems Pharmacology
22. Fluid volume kinetics of dilutional hyponatremia; a shock syndrome revisited
    R. Hahn, T. Gebäck · 2014 · Clinics
23. Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody.
    J. Duconge, R. Castillo, T. Crombet, D. Alvarez, J. Matheu, Gloria Vecino, Katia Alonso, I. Beausoleil, C. Valenzuela, María A. Bécquer et al. · 2004 · European Journal of Pharmaceutical Sciences
24. Light, Water, and Melatonin: The Synergistic Regulation of Phase Separation in Dementia
    Doris Loh, Russel Joseph Reiter · 2023 · International Journal of Molecular Sciences
25. Optimization of the traditional processing method for precision detoxification of CaoWu through biomimetic linking kinetics and human toxicokinetics of aconitine as toxic target marker.
    Han-Qing Li, Jia-Yin Xu, Xiao-Hong Fan, Shan-Shan Wu · 2019 · Journal of Ethnopharmacology
26. Glycine 1.5% for Irrigation Should Be Abandoned
    R. Hahn · 2013 · Urologia internationalis
27. A new approach to predicting human hepatic clearance of CYP3A4 substrates using monkey pharmacokinetic data
    Kotaro Ogawa, Motohiro Kato, Takao Houjo, Masaki Ishigai · 2012 · Xenobiotica
28. Prediction of a potentially effective dose in humans for BAY 60–5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically‐based pharmacokinetic modelling
    Olaf Weber, Stefan Willmann, Hilmar Bischoff, Volkhart Li, Alexandros Vakalopoulos, Klemens Lustig, Frank‐Thorsten Hafner, Roland Heinig, Carsten Schmeck, Klaus Buehner · 2011 · British Journal of Clinical Pharmacology
29. Risk Assessment in Extrapolation of Pharmacokinetics from Preclinical Data to Humans
    Zvi Teitelbaum, Thierry Lavé, Jan I. Freijer, Adam F. Cohen · 2010 · Clinical Pharmacokinetics
30. Bioavailability of glycyrrhizin from Shaoyao‐Gancao‐Tang in laxative‐treated rats
    Emi Goto, Jun-Xian He, T. Akao, T. Tani · 2005 · The Journal of pharmacy and pharmacology
31. Use of human airway smooth muscle in vitro and ex vivo to investigate drugs for the treatment of chronic obstructive respiratory disorders
    Luigino Calzetta, Clive Peter Page, Maria Gabriella Matera, Mario Cazzola, Paola Rogliani · 2023 · British Journal of Pharmacology
32. Turn On, Tune In, Turnover! Target Biology Impacts In Vivo Potency, Efficacy, and Clearance
    Johan Gabrielsson, Stephan Hjorth · 2023 · Pharmacological Reviews
33. The influence of age and body weight gain on enrofloxacin pharmacokinetics in turkeys-Allometric approach to dose optimization.
    B. Poźniak, M. Tikhomirov, K. Motykiewicz-Pers, K. Bobrek, M. Świtała · 2019 · Journal of Veterinary Pharmacology and Therapeutics
34. Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy
    Philippe Bernard Pierrillas, Émilie Hénin, Kathryn Ball, Julien R. Ogier, Magali Amiel, Laurence Kraus‐Berthier, Marylore Chenel, François Bouzom, Michel M. Tod · 2019 · Drug Metabolism and Disposition
35. Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agents
    Tim Cardilin, J. Almquist, M. Jirstrand, A. Zimmermann, Floriane Lignet, S. el Bawab, J. Gabrielsson · 2019 · Cancer Chemotherapy and Pharmacology
36. Review: Using physiologically based models to predict population responses to phytochemicals by wild vertebrate herbivores
    Jennifer S. Forbey, R. Liu, T. Trevor Caughlin, Marjorie D. Matocq, John A. Vucetich, Kevin D. Kohl, M. Denise Dearing, Annika M. Felton · 2018 · animal
37. Lost in translation: What's in an EC50? Innovative PK/PD reasoning in the drug development context.
    J. Gabrielsson, L. Peletier, S. Hjorth · 2018 · European Journal of Pharmacology
38. PulmoBind, an Adrenomedullin-Based Molecular Lung Imaging Tool
    M. Létourneau, Q. Nguyen, F. Harel, A. Fournier, J. Dupuis · 2013 · Journal of Nuclear Medicine
39. Interspecies scaling: prediction of human biliary clearance and comparison with QSPKR
    Marilyn E. Morris, Xinning Yang, Yash Gandhi, Suraj G. Bhansali, Lisa Jo Benincosa · 2011 · Biopharmaceutics & Drug Disposition
40. Disposition of a novel and potent α v β 3 antagonist in animals, and extrapolation to man
    Thomayant Prueksaritanont, Carmen Fernández‐Metzler, Y. Meng, Andrea Barrish, Wasyl Halczenko, Sevgi B. Rodan, John H. Hutchinson, M. E. DUGGAN, Jiunn Huei Lin · 2004 · Xenobiotica
41. Pharmacokinetics and disposition of a novel NMDA glycine site antagonist (UK-240,455) in rats, dogs and man
    Rob Webster, S. Cole, J. Gedge, S. Roffey, D. Walker, W. Wild · 2003 · Xenobiotica; the fate of foreign compounds in biological systems
42. Developing a computational pharmacokinetic model of systemic snakebite envenomation and antivenom treatment
    Natalie M Morris, Johanna A. Blee, Sabine Hauert · 2022 · Toxicon
43. Preclinical in vitro and in vivo pharmacokinetic properties of danicamtiv, a new targeted myosin activator for the treatment of dilated cardiomyopathy
    Mark P. Grillo, Svetlana Markova, Marc J. Evanchik, Marc Trellu, Patricia Moliner, Priscilla Brun, Anne Perreard‐Dumaine, Pascale Vicat, Chun Zhi Yang, James P. Driscoll et al. · 2020 · Xenobiotica
44. Successful Prediction of Human Pharmacokinetics by Improving Calculation Processes of Physiologically Based Pharmacokinetic Approach.
    Kei Mayumi, Shuichi Ohnishi, H. Hasegawa · 2019 · Journal of Pharmacy and Science
45. Drug solubility classification in the dog.
    Marilyn N. Martinez, M. Papich · 2012 · Journal of Veterinary Pharmacology and Therapeutics
46. Uptake Kinetics, Species Differences, and the Determination of Equivalent Combinations of Air Concentration and Exposure Duration for Assessment of Acute Inhalation Toxicity
    L. Rhomberg · 2009
47. Prediction of Human Bioavailability from Human Oral Administration Data and Animal Pharmacokinetic Data Without Data from Intravenous Administration of Drugs in Humans
    H. Imawaka, Kiyomi Ito, Yoshiaki Kitamura, K. Sugiyama, Y. Sugiyama · 2009 · Pharmaceutical Research
48. Repetitive administration of Shaoyao‐Gancao‐tang to rats restores the bioavailability of glycyrrhizin reduced by antibiotic treatment
    Jun-Xian He, T. Akao, T. Tani · 2003 · The Journal of pharmacy and pharmacology
49. Prediction of aztreonam pharmacokinetics in humans based on data from animals
    E. Swabb, D. Bonner · 1983 · Journal of pharmacokinetics and biopharmaceutics
50. Toxicokinetics: A Guidance for Assessing Systemic Exposure in Toxicology Studies, Where Are We Now; An S3A/S3B Update (1995–2011)
    B. Campbell, B. Ings · 2013 · AAPS advances in the pharmaceutical sciences series
51. In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor
    R. Sukhun, Peadar A Cremin, Donghong Xu, Jeanelle Zamora, Jennifer Cheung, Luke W. Ashcraft, M. Grillo, Bradley P. Morgan · 2024 · Xenobiotica; the fate of foreign compounds in biological systems
52. Preclinical Pharmacokinetics and Dosimetry of an 89Zr Labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model
    Anis Krache, Charlotte Fontan, Carine Pestourie, Manuel Bardiès, Yann Bouvet, Pierre Payoux, Étienne Chatelut, Mélanie White‐Koning, Anne‐Sophie Salabert · 2022 · Frontiers in Medicine
53. Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates
    Sarah Kim, Charles A. Scanga, Carolina de Miranda Silva, Matthew D. Zimmerman, Chelsea M. Causgrove, Brianne Stein, Veronique Anne Dartois, Charles A. Peloquin, Emily Graham, Arnold Louie et al. · 2020 · European Journal of Pharmaceutical Sciences
54. A Quantitative Systems Pharmacology Model for the Key Interleukins Involved in Crohn's Disease
    Violeta Balbas-Martinez, E. Asín-Prieto, Z. Parra-Guillén, I. Trocóniz · 2019 · Journal of Pharmacology and Experimental Therapeutics
55. Systematic Evaluation of Wajima Superposition (Steady-State Concentration to Mean Residence Time) in the Estimation of Human Intravenous Pharmacokinetic Profile.
    F. Lombardo, Giuliano Berellini, Laura R Labonte, Guiqing Liang, Sean Kim · 2016 · Journal of Pharmacy and Science
56. Comparison of bioequivalence study regulatory requirements for human and veterinary drugs.
    T. Grabowski, Monika Marczak, J. Jaroszewski, M. Whitmire · 2012 · Regulatory toxicology and pharmacology : RTP
57. Clearance of rFVIIa and NN1731 after intravenous administration to Beagle dogs.
    H. Agersø, N. Kristensen, H. Østergaard, D. M. Karpf, M. B. Hermit, H. Pelzer, L. C. Petersen, M. Ezban · 2011 · European Journal of Pharmaceutical Sciences
58. In vitroandin vivopharmacokinetic characterizations of AMG 900, an orally bioavailable small molecule inhibitor of aurora kinases
    Liyue Huang, Xuhai Be, Loren Berry, Earl Moore, Brett Janosky, Mary C. Wells, Wei‐Jian Pan, Zhiyang Zhao, Min-Hwa Jasmine Lin · 2011 · Xenobiotica
59. Interspecies scaling of a camptothecin analogue: Human predictions for intravenous topotecan using animal data
    P. Ahlawat, N. Srinivas · 2008 · Xenobiotica; the fate of foreign compounds in biological systems
60. Pharmacokinetic prediction for intravenous beta-lactam antibiotics in pediatric patients.
    K. Shimamura, T. Wajima, Y. Yano · 2007 · Journal of Pharmacy and Science
61. Interspecies scaling: predicting clearance of anticancer drugs in humans
    Iftekhar Mahmood · 1996 · European journal of drug metabolism and pharmacokinetics
62. Allometric analysis of tylosin tartrate pharmacokinetics in growing male turkeys
    B. Poźniak, M. Tikhomirov, K. Motykiewicz-Pers, K. Bobrek, M. Świtała · 2020 · Journal of Veterinary Sciences
63. Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats
    Ruihong Yu, Dawei Song, Debra C. DuBois, Richard R. Almon, William J. Jusko · 2019 · The AAPS Journal
64. TNF ‐α level affects etanercept clearance: TNF ‐α concentration as a new correction factor of allometric scaling to predict individual etanercept clearances in patients with ankylosing spondylitis
    Yuwei Deng, Li Hu, Wei Qiang, Zeneng Cheng, Lei Wang, Xiaoxia Wang · 2018 · Clinical and Experimental Pharmacology and Physiology
65. Prediction of Human Pharmacokinetics of Ulixertinib, a Novel ERK1/2 Inhibitor from Mice, Rats, and Dogs Pharmacokinetics
    Suresh Ponnayyan Sulochana, Ravi Kumar Jairam, Devaraj V. Chandrasekhar, A. B. Vinod, Rakesh A. Hiremath, Anusha Raj, Mohd Zainuddin, Ravi Kanth Bhamidipati, Ramesh Mullangi · 2018 · European Journal of Drug Metabolism and Pharmacokinetics
66. An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor
    Melanie I. Titze, O. Schaaf, M. H. Hofmann, M. Sanderson, S. Zahn, Jens Quant, T. Lehr · 2017 · Cancer Chemotherapy and Pharmacology
67. Quantifying Beta‐Galactosylceramide Kinetics in Cerebrospinal Fluid of Healthy Subjects Using Deuterium Labeling
    Kawita M. S. Kanhai, Sebastiaan Camiel Goulooze, Jasper Stevens, Justin L. Hay, Gersham W. Dent, Ajay Verma, Thomas Hankemeier, T. de Boer, Henri Meijering, JC Chavez et al. · 2016 · Clinical and Translational Science
68. Allometric Scaling of Therapeutic Monoclonal Antibodies Using Antigen Concentration as a Correction Factor: Application to the Human Clearance Prediction
    Lei Wang, Wei Qiang, Zeneng Cheng · 2016 · Journal of Pharmaceutical Sciences
69. Interspecies Allometric Scaling of Antimalarial Drugs and Potential Application to Pediatric Dosing
    S M D K Ganga Senarathna, Kevin T. Batty · 2014 · Antimicrobial Agents and Chemotherapy
70. Allometry of Factor VIII and Informed Scaling of Next-Generation Therapeutic Proteins
    Matthew P. Kosloski, Dipak S. Pisal, Donald E. Mager, Sathy V. Balu‐Iyer · 2013 · Journal of Pharmaceutical Sciences
71. Comparative Evaluation of US Food and Drug Administration and Pharmacologically Guided Approaches to Determine the Maximum Recommended Starting Dose for First-in-Human Clinical Trials in Adult Healthy Men
    Mohammad Tarique Imam, S. P. Venkateshan, Monika Tandon, Nilanjan Saha, K.K. Pillai · 2011 · The Journal of Clinical Pharmacology
72. Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic–pharmacodynamic modelling ofN-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor
    Bianca M. Liederer, Leonid M. Berezhkovskiy, Brian J. Dean, Vikki Dinkel, Jing Peng, Mark A. Merchant, Emile G. Plise, Harvey Wong, Xingrong Liu · 2010 · Xenobiotica
73. Application of allometry principles for the prediction of human pharmacokinetic parameters for irbesartan, a AT1 receptor antagonist, from animal data
    Venkata V. Pavan Kumar, Nuggehally R. Srinivas · 2008 · European journal of drug metabolism and pharmacokinetics
74. Pharmacokinetics of Nanomaterials
    J. Riviere · 2007
75. Evolution of human pharmacokinetics prediction methods: from allometry to artificial intelligence
    Nayoung Choi, Beom Soo Shin, Soyoung Shin · 2026 · Journal of Pharmaceutical Investigation
76. Application of the Population Pharmacokinetics Model-Based Approach to the Prediction of Drug–Drug Interaction between Rivaroxaban and Carbamazepine in Humans
    Lien Thi Ngo, Hwi‐yeol Yun, Jung‐woo Chae · 2023 · Pharmaceuticals
77. Improved Human Pharmacokinetic Prediction of Hepatically Metabolized Drugs With Species-Specific Systemic Clearance
    Kana Horiuchi, Shuichi Ohnishi, Takanobu Matsuzaki, Satoko Funaki, Ayahisa Watanabe, Tohru Mizutare, Sayaka Matsumoto, Ken‐ichi Nezasa, Hiroshi Hasegawa · 2018 · Journal of Pharmaceutical Sciences
78. Translational mixed‐effects PKPD modelling of recombinant human growth hormone – from hypophysectomized rat to patients
    A. Thorsted, P. Thygesen, H. Agersø, T. Laursen, M. Kreilgaard · 2016 · British Journal of Pharmacology
79. Prediction of drug concentration-time data in humans from animals: a comparison of three methods
    Iftekhar Mahmood, Kosalaram Goteti · 2012 · Xenobiotica
80. Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species
    Edna F. Choo, James P. Driscoll, Jian Q. Feng, Bianca M. Liederer, Emile G. Plise, Nikole Randolph, Young Geun Shin, Susan Wong, Yawei Ran · 2009 · Xenobiotica
81. Encapsulation and Targeted Release
    Bin Liu, Lulu Jiao, Jingjing Chai, Cheng Bao, Ping Jiang, Yuan Li · 2021 · Springer eBooks
82. Species Similarities and Differences in Pharmacokinetics and Distribution of Antiretroviral Drugs
    Andrew Owen, Paul Curley · 2014 · Springer eBooks
83. Evaluation and translation of combination therapies in oncology – A quantitative approach
    Tim Cardilin, J.O. Almquist, Mats Jirstrand, Johan Gabrielsson · 2018 · European Journal of Pharmacology
84. Mechanistic investigations into the species differences in pinometostat clearance: impact of binding to alpha-1-acid glycoprotein and permeability-limited hepatic uptake
    Sherri A. Smith, Sandra Gagnon, Nigel J. Waters · 2016 · Xenobiotica
85. Interspecies Pharmacokinetics. 1. Allometric Scaling of Pharmacokinetic Parameters (a Review)
    О. В. Полехина, Nicolay Vladimirovich Obraztsov, Victor Alexeevich Petrunin, T. A. Vysotskaya · 2014 · Pharmaceutical Chemistry Journal
86. Preliminary Assessment of Zolpidem Pharmacokinetics in Pediatric Burn Patients
    C. Stockmann, Catherine M Sherwin, Whitney M. Buterbaugh, M. Spigarelli, M. Gottschlich, D. Healy, R. Kagan · 2014 · Therapeutic Drug Monitoring
87. Equation chapter 1 section 1A new method for predicting human hepatic clearance fromin Vitro experimental data using molecular descriptors
    Soyoung Lee, Dongsup Kim · 2007 · Archives of Pharmacal Research
88. Inter-Species Pharmacokinetic Modeling and Scaling for Drug Repurposing of Pyronaridine and Artesunate
    Dong Wook Kang, Ju Hee Kim, Kyung‐Min Kim, Seok-jin Cho, Go-Wun Choi, Hea‐Young Cho · 2024 · International Journal of Molecular Sciences
89. Neuroprotective efficacy of hypothermia and Inter-alpha Inhibitor Proteins after hypoxic ischemic brain injury in neonatal rats
    Xiao-Di F. Chen, Yuehua Wu, Boram Kim, Kevin V. Nguyen, Ainuo Chen, Joseph Qiu, Andreas Santoso, Clémence Disdier, Y. Lim, Barbara S. Stonestreet · 2024 · Neurotherapeutics
90. Pharmacokinetic evaluation of a single chain antibody fragment against scorpion toxins in sheep.
    Roberto Olivares Hernández, Lidia Riaño Umbarila, B. Becerril, Alejandro Alagón Cano, Hilda Vázquez-López · 2024 · Toxicon
91. CNS penetration of methotrexate and its metabolite 7-hydroxymethotrexate in mice bearing orthotopic Group 3 medulloblastoma tumors and model-based simulations for children.
    R. S. Perkins, Abigail D. Davis, O. Campagne, Thandranese S. Owens, C. Stewart · 2022 · Drug Metabolism and Pharmacokinetics
92. Application of an Inter-Species Extrapolation Method for the Prediction of Drug Interactions between Propolis and Duloxetine in Humans
    Lien Thi Ngo, Chung-Hee Lee, Nayoung Han, Hyun‐moon Back, Su‐jin Rhee, Keumhan Noh, Hwi‐yeol Yun, Wonku Kang, Jung‐woo Chae · 2020 · International Journal of Molecular Sciences
93. Quantitative Prediction of Human Pharmacokinetics and Pharmacodynamics of CKD519, a Potent Inhibitor of Cholesteryl Ester Transfer Protein (CETP)
    Suein Choi, Seunghoon Han, Sangil Jeon, Dong‐Seok Yim · 2019 · Pharmaceutics
94. Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2
    Weon Sup Lee, Sang Ryeol Shim, Seon Young Lee, Jin San Yoo, Sung Kweon Cho · 2018 · Drug Design Development and Therapy
95. Interspecies scaling of excretory amounts using allometry – retrospective analysis with rifapentine, aztreonam, carumonam, pefloxacin, miloxacin, trovafloxacin, doripenem, imipenem, cefozopran, ceftazidime, linezolid for urinary excretion and rifapentine, cabotegravir, and dolutegravir for fecal excretion
    Nuggehally R. Srinivas · 2015 · Xenobiotica
96. Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin.
    R. R. Gilibili, R. Bhamidipati, R. Mullangi, N. Srinivas · 2015 · Journal of Pharmacy & Pharmaceutical Sciences
97. Pharmacokinetics and Pharmacodynamics of two Vitamin K1 Formulations in Rats
    L. Ma, Y. Cao, Lin Chen, Qingqing Xiao, Jin Yang · 2014 · Drug Research
98. Quantifying Immune Response to Influenza Virus Infection via Multivariate Nonlinear ODE Models with Partially Observed State Variables and Time-Varying Parameters
    Hulin Wu, Hongyu Miao, Hongqi Xue, David J. Topham, Martin Stuart Zand · 2014 · Statistics in Biosciences
99. Recent advances in pharmacokinetic extrapolation from preclinical data to humans
    Keith W. Ward · 2005 · Expert Opinion on Drug Metabolism & Toxicology
100. Prediction of differences inin vivooral clearance ofN,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxy)phenyl]ethylamine monohydrochloride (NE-100) between extensive and poor metabolizers fromin vitrometabolic data in human liver microsomes lacking CYP2D6 activity and recombinant CYPs
     Takahiko Yamamoto, Naoko Hagima, M. Nakamura, Yoshiro Kohno, Kiyoshi Nagata, Yasushi Yamazoe · 2004 · Xenobiotica